China Biologic Products 10-Q 2 Nov 16 2016 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 02, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Entity Registrant Name	China Biologic Products, Inc.
Entity Central Index Key	1,369,868
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Trading Symbol	CBPO
Entity Common Stock, Shares Outstanding		27,137,825

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current Assets
Cash and cash equivalents	$ 203,203,969	$ 144,937,893
Time deposits	0	38,032,593
Accounts receivable, net of allowance for doubtful accounts	40,188,813	25,144,969
Inventories	146,936,115	126,395,312
Prepayments and other current assets, net of allowance for doubtful accounts	37,516,102	24,545,597
Loan receivable-current	5,990,000	0
Deposits related to land use rights, current portion	1,038,403	10,056,200
Total Current Assets	434,873,402	369,112,564
Property, plant and equipment, net	134,424,469	105,364,251
Land use rights, net	24,196,851	23,576,300
Equity method investment	9,615,421	8,718,133
Loan receivable-non current	44,925,000	39,834,173
Other non-current assets	2,210,485	4,861,075
Total Assets	650,245,628	551,466,496
Current Liabilities
Accounts payable	7,154,609	9,681,835
Other payables and accrued expenses	54,753,124	57,462,563
Income tax payable	10,489,807	4,510,986
Total Current Liabilities	72,397,540	71,655,384
Deferred income	4,026,403	4,525,867
Other liabilities	6,859,244	8,323,446
Total Liabilities	83,283,187	84,504,697
Stockholders’ Equity
Common stock: par value $0.0001;100,000,000 shares authorized; 29,392,529 and 28,835,053 shares issued at September 30, 2016 and December 31, 2015, respectively; 27,137,825 and 26,580,349 shares outstanding at September 30, 2016 and December 31, 2015, respectively	2,939	2,884
Additional paid-in capital	125,123,106	105,079,845
Treasury stock: 2,254,704 shares at September 30, 2016 and December 31, 2015, at cost	(56,425,094)	(56,425,094)
Retained earnings	419,045,745	333,704,094
Accumulated other comprehensive income	(11,801,219)	(18,605)
Total equity attributable to China Biologic Products, Inc.	475,945,477	382,343,124
Noncontrolling interest	91,016,964	84,618,675
Total Stockholders’ Equity	566,962,441	466,961,799
Commitments and contingencies
Total Liabilities and Stockholders’ Equity	$ 650,245,628	$ 551,466,496

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Common Stock, Par Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	29,392,529	28,835,053
Common Stock, Shares, Outstanding	27,137,825	26,580,349
Treasury Stock, Shares	2,254,704	2,254,704

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Sales	$ 86,525,885	$ 78,750,577	$ 263,534,751	$ 228,173,360
Cost of sales	27,647,338	27,944,878	93,172,919	79,461,079
Gross profit	58,878,547	50,805,699	170,361,832	148,712,281
Operating expenses
Selling expenses	3,017,184	2,674,434	7,271,311	7,229,782
General and administrative expenses	15,095,872	11,510,981	38,997,568	27,485,566
Research and development expenses	1,042,806	1,595,140	3,441,344	3,984,447
Income from operations	39,722,685	35,025,144	120,651,609	110,012,486
Other income (expenses)
Equity in income (loss) of an equity method investee	1,097,338	(376,260)	1,140,873	(1,137,560)
Interest expense	(57,661)	(101,290)	(234,739)	(1,533,971)
Interest income	1,865,805	1,383,142	4,909,014	4,227,124
Loss from disposal of a subsidiary	(75,891)	0	(75,891)	0
Total other income, net	2,829,591	905,592	5,739,257	1,555,593
Earnings before income tax expense	42,552,276	35,930,736	126,390,866	111,568,079
Income tax expense	7,163,708	6,052,353	20,777,575	17,792,164
Net income	35,388,568	29,878,383	105,613,291	93,775,915
Less: Net income attributable to noncontrolling interest	6,997,207	7,001,833	20,271,640	21,012,934
Net income attributable to China Biologic Products, Inc.	$ 28,391,361	$ 22,876,550	$ 85,341,651	$ 72,762,981
Net income per share of common stock:
Basic	$ 1.02	$ 0.86	$ 3.1	$ 2.81
Diluted	$ 1.01	$ 0.82	$ 3.05	$ 2.68
Weighted average shares used in computation:
Basic	26,957,205	25,992,776	26,748,141	25,280,538
Diluted	27,297,118	27,056,215	27,193,108	26,488,730
Net income	$ 35,388,568	$ 29,878,383	$ 105,613,291	$ 93,775,915
Other comprehensive income:
Foreign currency translation adjustment, net of nil income taxes	(3,543,648)	(15,704,961)	(14,241,256)	(15,095,718)
Comprehensive income	31,844,920	14,173,422	91,372,035	78,680,197
Less: Comprehensive income attributable to noncontrolling interest	6,365,548	4,015,428	17,812,998	18,302,111
Comprehensive income attributable to China Biologic Products, Inc.	$ 25,479,372	$ 10,157,994	$ 73,559,037	$ 60,378,086

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 105,613,291	$ 93,775,915
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	6,946,084	6,103,812
Amortization	678,981	637,301
Loss on sale of property, plant and equipment and land use rights	215,778	363,857
Allowance for doubtful accounts - accounts receivable, net	120,535	35,162
Allowance for doubtful accounts - other receivables and prepayments	45,537	793
Impairment for other non-current assets	1,225,200	0
Write-down of obsolete inventories	90,202	16,650
Deferred tax benefit	(1,710,855)	(55,232)
Share-based compensation	16,315,667	7,640,894
Equity in (income) loss of an equity method investee	(1,140,873)	1,137,560
Loss from disposal of a subsidiary	75,891	0
Excess tax benefits from share-based compensation arrangements	0	(288,681)
Change in operating assets and liabilities:
Accounts receivable	(16,104,694)	(16,229,405)
Prepayment and other current assets	(497,812)	742,586
Inventories	(24,493,697)	(26,058,886)
Accounts payable	(2,295,197)	659,077
Other payables and accrued expenses	(3,553,823)	4,240,643
Deferred income	(411,765)	(284,053)
Income tax payable	6,198,276	(170,407)
Net cash provided by operating activities	87,316,726	72,267,586
CASH FLOWS FROM INVESTING ACTIVITIES:
Payment for property, plant and equipment	(40,955,964)	(26,310,114)
Payment for intangible assets and land use rights	(1,572,919)	(4,199,308)
Refund of deposits related to land use right	10,297,893	0
Proceeds from sale of property, plant and equipment and land use rights	351,524	741,980
Loans lent to a third party	(12,332,718)	(28,450,202)
Proceeds from disposal of a subsidiary	128,654	0
Receipt of government grants related to property and equipment	0	2,452,864
Net cash used in investing activities	(44,083,530)	(55,764,780)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from stock option exercised	3,214,253	7,220,483
Repayment of bank loans	0	(97,910,360)
Maturity of deposit as security for bank loans	37,756,405	63,152,258
Payment to noncontrolling interest shareholders in connection with their capital withdrawal	(13,502,700)	0
Excess tax benefits from share-based compensation arrangements	0	288,681
Dividend paid by subsidiaries to noncontrolling interest shareholders	(7,921,952)	0
Net proceeds from reissuance of treasury stock	0	80,583,959
Dividend to the trial court to be held in escrow as to dispute with Jie’an	0	(3,690,814)
Net cash provided by financing activities	19,546,006	49,644,207
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	(4,513,126)	(4,306,828)
NET INCREASE IN CASH AND CASH EQUIVALENTS	58,266,076	61,840,185
Cash and cash equivalents at beginning of period	144,937,893	80,820,224
Cash and cash equivalents at end of period	203,203,969	142,660,409
Supplemental cash flow information
Cash paid for income taxes	16,305,759	18,073,863
Cash paid for interest expense	0	1,426,883
Noncash investing and financing activities:
Acquisition of property, plant and equipment included in payables	$ 5,512,453	$ 1,990,043

BASIS OF PRESENTATION, SIGNIFIC

BASIS OF PRESENTATION, SIGNIFICANT CONCENTRATION AND RISKS	9 Months Ended
	Sep. 30, 2016
Basis Of Presentation Significant Concentration and Risks [Abstract]
BASIS OF PRESENTATION, SIGNIFICANT CONCENTRATION AND RISKS	NOTE 1 – BASIS OF PRESENTATION, SIGNIFICANT CONCENTRATION AND RISKS (a) Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted by rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The December 31, 2015 consolidated balance sheet was derived from the audited consolidated financial statements of China Biologic Products, Inc. (the “Company”). The accompanying unaudited consolidated financial statements should be read in conjunction with the December 31, 2015 audited consolidated financial statements of the Company included in the Company’s annual report on Form 10-K for the year ended December 31, 2015. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the financial position as of September 30, 2016, the results of operations for the three and nine months ended September 30, 2016 and 2015, and cash flows for the nine months ended September 30, 2016 and 2015, have been made. All significant intercompany transactions and balances are eliminated on consolidation. The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the useful lives of property, plant and equipment and intangibles with definite lives, the allowances for doubtful accounts, the fair value determinations of stock compensation awards, the realizability of deferred tax assets and inventories, the recoverability of intangible assets, land use rights, property, plant and equipment, equity method investment and loan receivable, and accruals for income tax uncertainties and other contingencies. (b) Explanatory Note For the reasons discussed below, the Company has corrected the number of the authorized shares of common stock from 1,000,000,000 In connection with the 2016 annual meeting of stockholders (the “Annual Meeting”), the Company filed a definitive proxy statement on Schedule 14A on April 29, 2016 that included a proposal to amend the Company’s certificate of incorporation to increase the number of authorized shares of common stock from 100,000,000 1,000,000,000 The Company considers such revision to be immaterial and the revision had no impact on the unaudited condensed consolidated financial statements other than disclosure of the number of shares authorized on the face of the balance sheets (c) Significant Concentration and Risks The Company’s operations are carried out in the People’s Republic of China (the “PRC”) and are subject to specific considerations and significant risks not typically associated with companies in North America and Western Europe. Accordingly, the Company’s business, financial condition and results of operations may be influenced by the political, economic and legal environment in the PRC, and by the general state of the PRC economy. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other matters. The Company maintains cash and deposit balances at financial institutions which, from time to time, may exceed Federal Deposit Insurance Corporation insured limits for its bank accounts located in the United States or may exceed Hong Kong Deposit Protection Board insured limits for its bank accounts located in Hong Kong or may exceed the insured limits for its bank accounts in China established by China Deposit Insurance Fund Management Institution. Total cash at banks and deposits as of September 30, 2016 and December 31, 2015 amounted to $ 202,109,273 182,291,723 2,461,610 3,020,569 The Company’s two major products are human albumin and human immunoglobulin for intravenous injection (“IVIG”). Human albumin accounted for 37.0 38.7 38.9 37.5 33.1 41.4 35.5 43.6 Substantially all of the Company’s customers are located in the PRC. There were no customers that individually comprised 10% or more of the total sales during the three months and nine months ended September 30, 2016 and September 30, 2015. There was no customer represented more than 10% of accounts receivables as at September 30, 2016 and December 31, 2015, respectively. The Company performs ongoing credit evaluations of its customers’ financial condition and, generally, requires no collateral from its customers. There was one supplier, namely, Xinjiang Deyuan Bioengineering Co., Ltd. (“Xinjiang Deyuan”), that comprised 10% or more of the total purchases for the three months and nine months ended September 30, 2016 and September 30, 2015, respectively. There was no supplier that represented more than 10% of accounts payables as at September 30, 2016. There was one supplier that represented more than 10% of accounts payables as at December 31, 2015.

ACCOUNTS RECEIVABLE

ACCOUNTS RECEIVABLE	9 Months Ended
	Sep. 30, 2016
Accounts Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
ACCOUNTS RECEIVABLE	NOTE 2 – ACCOUNTS RECEIVABLE September 30, December 31, USD USD Accounts receivable 40,740,371 25,588,593 Less: Allowance for doubtful accounts (551,558) (443,624) Total 40,188,813 25,144,969 For the Nine Months Ended September 30, September 30, USD USD Beginning balance 443,624 433,948 Provisions 120,535 35,162 Recoveries - - Write-offs - - Foreign currency translation adjustment (12,601) (16,268) Ending balance 551,558 452,842

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 3 – INVENTORIES September 30, December 31, USD USD Raw materials 76,193,306 57,418,230 Work-in-process 31,160,904 27,401,062 Finished goods 39,581,905 41,576,020 Total 146,936,115 126,395,312 An inventory write-down of $ 28,705 90,202 16,650

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	9 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 4 – PROPERTY, PLANT AND EQUIPMENT September 30, December 31, USD USD Buildings 35,370,056 31,505,133 Machinery and equipment 54,051,332 54,640,502 Furniture, fixtures, office equipment and vehicles 7,880,888 7,859,951 Total property, plant and equipment, gross 97,302,276 94,005,586 Accumulated depreciation (36,235,207) (31,521,859) Total property, plant and equipment, net 61,067,069 62,483,727 Construction in progress 58,324,131 26,115,927 Prepayment for property, plant and equipment 15,033,269 16,764,597 Property, plant and equipment, net 134,424,469 105,364,251 Depreciation expense for the three months ended September 30, 2016 and 2015 was $ 2,356,056 1,980,213 6,946,084 6,103,812

DEPOSITS RELATED TO LAND USE RI

DEPOSITS RELATED TO LAND USE RIGHTS	9 Months Ended
	Sep. 30, 2016
Deposits Related To Land Use Rights [Abstract]
DEPOSITS RELATED TO LAND USE RIGHTS	NOTE 5 – DEPOSITS RELATED TO LAND USE RIGHTS In 2012, Guizhou Taibang made a refundable payment of RMB 83,400,000 12,489,150 13,000,000 1,946,750 10,000,000 1,497,500 59,665,759 8,934,947

LOAN RECEIVABLE

LOAN RECEIVABLE	9 Months Ended
	Sep. 30, 2016
Loans Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Customers represented 10% or more of accounts receivable	NOTE 6 – LOAN RECEIVABLE (a) Current In June 2016, the Company entered into a RMB 40,000,000 5,990,000 6 September 20, 2016 40,000,000 5,990,000 On October 18, 2016, the Company entered into a supplemental agreement to the loan agreement with Xinjiang Deyuan, pursuant to which the principal of the loan was agreed to offset purchase payment of plasma from Xinjiang Deyuan in two installments, with the remaining principal of the loan, if any, being repaid by Xinjiang Deyuan no later than December 20, 2016. The Company has the right to charge an interest rate of 9% per annum for any overdue loan since September 21, 2016 according to loan agreement. Interest income of $ 79,906 60,012 (b) Non-current In August 2015, the Company entered into a cooperation agreement with Xinjiang Deyuan and the controlling shareholder of Xinjiang Deyuan. Pursuant to the agreement, Guizhou Taibang agreed to provide Xinjiang Deyuan with interest-bearing loans at an interest rate of 6 300,000,000 44,925,000 July 31, 2018 258,663,461 38,734,853 41,336,539 6,190,147 Interest income of $ 638,622 1,985,767

INCOME TAX

INCOME TAX	9 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
INCOME TAX	NOTE 7 – INCOME TAX In October 2014, Shandong provincial government granted Shandong Taibang the High and New Technology Enterprise certificate. This certificate entitled Shandong Taibang to enjoy a preferential income tax rate of 15 According to Cai Shui [2011] No. 58 dated July 27, 2011, Guizhou Taibang, being a qualified enterprise located in the western region of PRC, enjoys a preferential income tax rate of 15 The Company’s effective income tax rates were 17 17 16 16 As of and for the three months ended September 30, 2016, the Company did not have any unrecognized tax benefits and thus no interest and penalties related to unrecognized tax benefits were recorded. In addition, the Company does not expect that the amount of unrecognized tax benefits to change significantly within the next 12 months.

OPTIONS AND NONVESTED SHARES

OPTIONS AND NONVESTED SHARES	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
OPTIONS AND NONVESTED SHARES	NOTE 8 – OPTIONS AND NONVESTED SHARES Options Number of Options Weighted Weighted Average Aggregate USD USD Outstanding at December 31, 2015 651,897 10.44 5.24 86,064,461 Granted - Exercised (304,826) 10.54 (31,741,472) Forfeited and expired - Outstanding at September 30, 2016 347,071 10.35 4.23 39,612,865 Vested 347,071 10.35 4.23 39,612,865 Exercisable at September 30, 2016 347,071 10.35 4.23 39,612,865 For the three months ended September 30, 2016 and 2015, the Company recorded stock compensation expense of $ 162,047 243,578 649,203 874,413 Nonvested shares Number of Grant date weighted USD Outstanding at December 31, 2015 669,100 77.49 Granted 511,200 119.75 Vested (252,650) 66.10 Forfeited (12,500) 66.74 Outstanding at September 30, 2016 915,150 104.39 For the three months ended September 30, 2016 and 2015, the Company recorded stock compensation expense of $ 6,846,521 3,363,835 15,666,464 6,766,481 At September 30, 2016, approximately $ 89,756,842 2.98

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 9 – FAIR VALUE MEASUREMENTS Management used the following methods and assumptions to estimate the fair value of financial instruments at the relevant balance sheet dates: • Short-term financial instruments (including cash and cash equivalents, time deposits, accounts receivable, other receivables, loan receivable-current, accounts payable, and other payables and accrued expenses) – The carrying amounts of the short-term financial instruments approximate their fair values because of the short maturity of these instruments. • Loan receivable-non current – The carrying amounts of loan receivable-non current approximate their fair value. The fair value is estimated using discounted cash flow analysis based on the Company’s incremental borrowing rates for similar borrowing.

SALES

SALES	9 Months Ended
	Sep. 30, 2016
Sales [Abstract]
SALES	NOTE 10 – SALES The Company’s sales are primarily derived from the manufacture and sale of Human Albumin and Immunoglobulin products. The Company’s sales by significant types of product for the three months ended September 30, 2016 and 2015 are as follows: For the Three Months Ended September 30, September 30, USD USD Human Albumin 32,050,728 30,442,931 Immunoglobulin products: Human Immunoglobulin for Intravenous Injection 28,608,129 32,610,967 Other Immunoglobulin products 13,449,552 4,951,787 Placenta Polypeptide 8,124,774 7,594,093 Others 4,292,702 3,150,799 Total 86,525,885 78,750,577 The Company’s sales by significant types of product for the nine months ended September 30, 2016 and 2015 are as follows: For the Nine Months Ended September 30, September 30, USD USD Human Albumin 102,387,387 85,538,413 Immunoglobulin products: Human Immunoglobulin for Intravenous Injection 93,439,551 99,552,008 Other Immunoglobulin products 30,555,619 15,936,561 Placenta Polypeptide 24,723,672 19,882,127 Others 12,428,522 7,264,251 Total 263,534,751 228,173,360

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 11 – COMMITMENTS AND CONTINGENCIES Commitments As of September 30, 2016, commitments outstanding for the purchase of property, plant and equipment approximated $ 27.8 As of September 30, 2016, commitments outstanding for the purchase of plasma from 2016 to 2018 approximated $ 57.2 Legal proceedings Dispute with Jie’an over Certain Capital Injection into Guizhou Taibang In May 2007, a 91 20,000,000 9 50,960,000 7,631,260 21.4 1,800,000 20,000,000 50,960,000 7,631,260 6,480,000 970,380 In June 2007, Jie’an brought a lawsuit against Guizhou Taibang, alleging that it had a right to acquire the 18,200,000 18,200,000 During the second quarter of 2010, Jie’an requested that Guizhou Taibang register its 1.8 In December 2013, Jie’an brought a third lawsuit against Guizhou Taibang, requesting Guizhou Taibang to register 1.8 13,809,197 2,067,927 1.8 18,339,227 2,746,299 22,639,227 3,390,224 In November 2013, Guizhou Taibang held a shareholders meeting and the shareholders passed resolutions, or the November 2013 Resolutions, that, inter alia, (i) determined that it was no longer necessary for Guizhou Taibang to obtain additional capital from investors; (ii) rejected Jie’an’s request that Jie’an subscribe for additional shares of Guizhou Taibang alone and one or more other shareholders reduce their shareholding in Guizhou Taibang; and (iii) approved the issuance of a total of 20,000,000 In March 2014, Guizhou Taibang held another shareholders meeting and the shareholders passed resolutions, or the March 2014 Resolutions, that, inter alia, re-calculated the ownership percentage in Guizhou Taibang based on the November 2013 Resolutions and the additional capital injections from existing shareholders. Guizhou Taibang subsequently updated the registration with the local AIC regarding the additional capital injections in August 2014. In September 2014, Jie’an and Shenzhen Yigong Shengda Technology Co., Ltd., or Yigong Shengda, another minority shareholder of Guizhou Taibang filed a lawsuit against Guizhou Taibang, requesting that the court declare both the November 2013 Resolutions and the March 2014 Resolutions void and instruct Guizhou Taibang to withdraw the AIC registration. In November 2014, the trial court suspended this case pending the final outcome of the third lawsuit filed by Jie’an. In October 2015, the trial court denied their request. In May 2016, the appellate court vacated the trial court’s decision to uphold Guizhou Taibang’s shareholders resolution, and remanded the case for retrial. In August 2016, the trial court granted the petitions by Jie’an and Yigong Shengda to withdraw the lawsuit as Jie’an and Yigong Shengda sought to withdraw their respective capital contributions in Guizhou Taibang pursuant to an agreement dated July 31, 2016. On July 31, 2016, Guiyang Dalin Biologic Technologies Co., Ltd., or Guiyang Dalin, Guizhou Taibang, Jie’an and Yigong Shengda entered into an agreement, pursuant to which Jie’an and Yigong Shengda agreed to withdraw their respective capital contributions in Guizhou Taibang for an aggregate consideration of RMB 415,000,000 62,146,250 90,000,000 13,502,700 As of September 30, 2016, Guizhou Taibang had maintained, on its balance sheet, payables to Jie’an in the amounts of RMB 5,040,000 754,740 1.8 1,440,000 215,640 3,913,734 586,082 Dispute with Certain Individual Investor over Certain Capital Injection into Guizhou Taibang In part due to the invalidity of the Equity Purchase Agreement with certain alleged strategic investors in May 2007, which was never approved or ratified by Guizhou Taibang’s shareholders, such investors’ equity ownership in Guizhou Taibang and the related increase in registered capital of Guizhou Taibang have never been registered with the local AIC. In January 2010, one individual among such investors brought a lawsuit against Guizhou Taibang requesting to register his 14.35 In October 2010, the trial court denied such individual investor’s right as shareholder of Guizhou Taibang and his entitlement to share the dividends, which ruling was reaffirmed after a re-trial by the same trial court in December 2012. After such ruling, Guizhou Taibang attempted to return the originally received fund of RMB 34,160,000 5,115,460 11,200,000 1,677,200 As of September 30, 2016, Guizhou Taibang had maintained, on its balance sheet, payables to the investors of RMB 34,160,000 5,115,460 18,895,852 2,829,654 341,600 51,155 1

NET INCOME PER SHARE

NET INCOME PER SHARE	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
NET INCOME PER SHARE	NOTE 12 - NET INCOME PER SHARE For the Three Months Ended September 30, 2016 September 30, 2015 USD USD Net income attributable to China Biologic Products, Inc. 28,391,361 22,876,550 Earnings allocated to participating nonvested shares (888,528) (572,297) Net income used in basic/diluted net income per common stock 27,502,833 22,304,253 Weighted average shares used in computing basic net income per common stock 26,957,205 25,992,776 Diluted effect of stock options 339,913 1,063,439 Weighted average shares used in computing diluted net income per common stock 27,297,118 27,056,215 Net income per common stock – basic 1.02 0.86 Net income per common stock – diluted 1.01 0.82 During the three months ended September 30, 2016 and 2015, no option was antidilutive or excluded from the calculation of diluted net income per common stock. For the Nine Months Ended September 30, 2016 September 30, 2015 USD USD Net income attributable to China Biologic Products, Inc. 85,341,651 72,762,981 Earnings allocated to participating nonvested shares (2,314,921) (1,656,974) Net income used in basic/diluted net income per common stock 83,026,730 71,106,007 Weighted average shares used in computing basic net income per common stock 26,748,141 25,280,538 Diluted effect of stock options 444,967 1,208,192 Weighted average shares used in computing diluted net income per common stock 27,193,108 26,488,730 Net income per common stock – basic 3.10 2.81 Net income per common stock – diluted 3.05 2.68 During the nine months ended September 30, 2016 and 2015, no option was antidilutive or excluded from the calculation of diluted net income per common stock.

RECENTLY ISSUED ACCOUNTING PRON

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2016
Accounting Changes and Error Corrections [Abstract]
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS	NOTE 13 – RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which modified lease accounting for both lessees and lessors to increase transparency and comparability by recognizing lease assets and lease liabilities by lessees for those leases classified as operating leases under previous accounting standards and disclosing key information about leasing arrangements. ASU 2016-02 is effective for public companies for annual reporting periods, and interim periods within those years, beginning after December 15, 2018. Early adoption is permitted. In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”), which simplified certain aspects of the accounting for share-based payment transactions, including income taxes, classification of awards and classification in the statement of cash flows. This standard will be effective for public companies for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments, which addressed and provided guidance for each of eight specific cash flow issues with the objective of reducing the existing diversity in practice. This standard will be effective for public companies for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact of adopting ASU 2016-15 on its consolidated financial statements. In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory. This standard required that companies recognize the income tax consequences of an intra-entity transfer of an asset (other than inventory) when the transfer occurs. Current guidance prohibits companies from recognizing current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party. This standard will be effective for public companies for annual periods beginning after December 15, 2017, including interim periods within that reporting period. The Company is currently evaluating the impact this guidance may have on its consolidated financial statements.

ACCOUNTS RECEIVABLE (Tables)

ACCOUNTS RECEIVABLE (Tables)	9 Months Ended
	Sep. 30, 2016
Receivables [Abstract]
SCHEDULE OF ACCOUNTS RECEIVABLE	Accounts receivable at September 30, 2016 and December 31, 2015 consisted of the following: September 30, December 31, USD USD Accounts receivable 40,740,371 25,588,593 Less: Allowance for doubtful accounts (551,558) (443,624) Total 40,188,813 25,144,969
SCHEDULE OF ACTIVITIES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS	The activity in the allowance for doubtful accounts-accounts receivable for the nine months ended September 30, 2016 and 2015 are as follows: For the Nine Months Ended September 30, September 30, USD USD Beginning balance 443,624 433,948 Provisions 120,535 35,162 Recoveries - - Write-offs - - Foreign currency translation adjustment (12,601) (16,268) Ending balance 551,558 452,842

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORIES	Inventories at September 30, 2016 and December 31, 2015 consisted of the following: September 30, December 31, USD USD Raw materials 76,193,306 57,418,230 Work-in-process 31,160,904 27,401,062 Finished goods 39,581,905 41,576,020 Total 146,936,115 126,395,312

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT	Property, plant and equipment at September 30, 2016 and December 31, 2015 consisted of the following: September 30, December 31, USD USD Buildings 35,370,056 31,505,133 Machinery and equipment 54,051,332 54,640,502 Furniture, fixtures, office equipment and vehicles 7,880,888 7,859,951 Total property, plant and equipment, gross 97,302,276 94,005,586 Accumulated depreciation (36,235,207) (31,521,859) Total property, plant and equipment, net 61,067,069 62,483,727 Construction in progress 58,324,131 26,115,927 Prepayment for property, plant and equipment 15,033,269 16,764,597 Property, plant and equipment, net 134,424,469 105,364,251

OPTIONS AND NONVESTED SHARES (T

OPTIONS AND NONVESTED SHARES (Tables)	9 Months Ended
	Sep. 30, 2016
Options and Nonvested Shares [Abstract]
SCHEDULE OF STOCK OPTIONS ACTIVITY	A summary of stock options activity for the nine months ended September 30, 2016 is as follow: Number of Options Weighted Weighted Average Aggregate USD USD Outstanding at December 31, 2015 651,897 10.44 5.24 86,064,461 Granted - Exercised (304,826) 10.54 (31,741,472) Forfeited and expired - Outstanding at September 30, 2016 347,071 10.35 4.23 39,612,865 Vested 347,071 10.35 4.23 39,612,865 Exercisable at September 30, 2016 347,071 10.35 4.23 39,612,865
SCHEDULE OF NONVESTED SHARES ACTIVITY	A summary of nonvested shares activity for the nine months ended September 30, 2016 is as follows: Number of Grant date weighted USD Outstanding at December 31, 2015 669,100 77.49 Granted 511,200 119.75 Vested (252,650) 66.10 Forfeited (12,500) 66.74 Outstanding at September 30, 2016 915,150 104.39

SALES (Tables)

SALES (Tables)	9 Months Ended
	Sep. 30, 2016
Sales Disclosure [Abstract]
SCHEDULE OF SALES BY PRODUCT TYPE	The Company’s sales by significant types of product for the three months ended September 30, 2016 and 2015 are as follows: For the Three Months Ended September 30, September 30, USD USD Human Albumin 32,050,728 30,442,931 Immunoglobulin products: Human Immunoglobulin for Intravenous Injection 28,608,129 32,610,967 Other Immunoglobulin products 13,449,552 4,951,787 Placenta Polypeptide 8,124,774 7,594,093 Others 4,292,702 3,150,799 Total 86,525,885 78,750,577 The Company’s sales by significant types of product for the nine months ended September 30, 2016 and 2015 are as follows: For the Nine Months Ended September 30, September 30, USD USD Human Albumin 102,387,387 85,538,413 Immunoglobulin products: Human Immunoglobulin for Intravenous Injection 93,439,551 99,552,008 Other Immunoglobulin products 30,555,619 15,936,561 Placenta Polypeptide 24,723,672 19,882,127 Others 12,428,522 7,264,251 Total 263,534,751 228,173,360

NET INCOME PER SHARE (Tables)

NET INCOME PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2016
Net Income Loss Per Share Disclosure [Abstract]
SCHEDULE OF EPS - BASIC AND DILUTED	The following table sets forth the computation of basic and diluted net income per share for the periods indicated: For the Three Months Ended September 30, 2016 September 30, 2015 USD USD Net income attributable to China Biologic Products, Inc. 28,391,361 22,876,550 Earnings allocated to participating nonvested shares (888,528) (572,297) Net income used in basic/diluted net income per common stock 27,502,833 22,304,253 Weighted average shares used in computing basic net income per common stock 26,957,205 25,992,776 Diluted effect of stock options 339,913 1,063,439 Weighted average shares used in computing diluted net income per common stock 27,297,118 27,056,215 Net income per common stock – basic 1.02 0.86 Net income per common stock – diluted 1.01 0.82 The following table sets forth the computation of basic and diluted net income per share for the periods indicated: For the Nine Months Ended September 30, 2016 September 30, 2015 USD USD Net income attributable to China Biologic Products, Inc. 85,341,651 72,762,981 Earnings allocated to participating nonvested shares (2,314,921) (1,656,974) Net income used in basic/diluted net income per common stock 83,026,730 71,106,007 Weighted average shares used in computing basic net income per common stock 26,748,141 25,280,538 Diluted effect of stock options 444,967 1,208,192 Weighted average shares used in computing diluted net income per common stock 27,193,108 26,488,730 Net income per common stock – basic 3.10 2.81 Net income per common stock – diluted 3.05 2.68

BASIS OF PRESENTATION, SIGNIF25

BASIS OF PRESENTATION, SIGNIFICANT CONCENTRATION AND RISKS (Narrative) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2016USD ($)shares	Sep. 30, 2015	Sep. 30, 2016USD ($)shares	Sep. 30, 2015	Jun. 30, 2016shares	Apr. 29, 2016shares	Dec. 31, 2015USD ($)shares
Basis Of Presentation Significant Concentration And Risk [Line Items]
Total cash at banks and deposits including insured amount	$ 202,109,273		$ 202,109,273				$ 182,291,723
Cash, Insured Amount	$ 2,461,610		$ 2,461,610				$ 3,020,569
Customers that individually comprised 10% or more of the total sales	0	0	0	0
Suppliers that comprised 10% or more of the total purchases	1	1	1	1
Customers represented 10% or more of accounts receivable	0		0				0
Suppliers that represented more than 10% of accounts payables	0		0				1
Common Stock, Shares Authorized | shares	100,000,000		100,000,000		1,000,000,000	1,000,000,000	100,000,000
Human Albumin [Member]
Basis Of Presentation Significant Concentration And Risk [Line Items]
Major product sales percentage	37.00%	38.70%	38.90%	37.50%
Human Immunoglobulin For Intravenous Injection [Member]
Basis Of Presentation Significant Concentration And Risk [Line Items]
Major product sales percentage	33.10%	41.40%	35.50%	43.60%

ACCOUNTS RECEIVABLE (Schedule O

ACCOUNTS RECEIVABLE (Schedule Of Accounts Receivable) (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 40,740,371	$ 25,588,593
Less: Allowance for doubtful accounts	(551,558)	(443,624)
Total	$ 40,188,813	$ 25,144,969

ACCOUNTS RECEIVABLE (Schedule27

ACCOUNTS RECEIVABLE (Schedule Of Activity in the Allowance for Doubtful Accounts) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	$ 443,624	$ 433,948
Provisions	120,535	35,162
Recoveries	0	0
Write-offs	0	0
Foreign currency translation adjustment	(12,601)	(16,268)
Ending balance	$ 551,558	$ 452,842

INVENTORIES (Narrative) (Detail

INVENTORIES (Narrative) (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015
Write-down of obsolete inventories	$ 28,705	$ 90,202	$ 16,650

INVENTORIES (Schedule Of Invent

INVENTORIES (Schedule Of Inventories) (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Inventory [Line Items]
Raw materials	$ 76,193,306	$ 57,418,230
Work-in-process	31,160,904	27,401,062
Finished goods	39,581,905	41,576,020
Total	$ 146,936,115	$ 126,395,312

PROPERTY, PLANT AND EQUIPMENT30

PROPERTY, PLANT AND EQUIPMENT (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Depreciation	$ 2,356,056	$ 1,980,213	$ 6,946,084	$ 6,103,812

PROPERTY, PLANT AND EQUIPMENT31

PROPERTY, PLANT AND EQUIPMENT (Schedule Of Property Plant And Equipment) (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	$ 97,302,276	$ 94,005,586
Accumulated depreciation	(36,235,207)	(31,521,859)
Total property, plant and equipment, net	61,067,069	62,483,727
Construction in progress	58,324,131	26,115,927
Prepayment for property, plant and equipment	15,033,269	16,764,597
Property, plant and equipment, net	134,424,469	105,364,251
Buildings [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	35,370,056	31,505,133
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	54,051,332	54,640,502
Furniture, Fixtures, Office Equipment and Vehicles [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	$ 7,880,888	$ 7,859,951

DEPOSITS RELATED TO LAND USE 32

DEPOSITS RELATED TO LAND USE RIGHTS (Narrative) (Details)	12 Months Ended
	Dec. 31, 2012USD ($)	Dec. 31, 2012CNY (¥)	Sep. 30, 2016USD ($)	Sep. 30, 2016CNY (¥)	Jan. 31, 2014USD ($)	Jan. 31, 2014CNY (¥)	Dec. 31, 2013USD ($)	Dec. 31, 2013CNY (¥)
Refunded deposits related to land use rights			$ 8,934,947	¥ 59,665,759	$ 1,497,500	¥ 10,000,000	$ 1,946,750	¥ 13,000,000
Use Rights [Member] | Land [Member]
Payment For Refundable Deposits	$ 12,489,150	¥ 83,400,000

LOAN RECEIVABLE (Narrative) (De

LOAN RECEIVABLE (Narrative) (Details)	1 Months Ended			3 Months Ended		9 Months Ended
	Oct. 18, 2016	Jun. 30, 2016USD ($)	Aug. 31, 2015USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Jul. 02, 2016USD ($)	Jul. 02, 2016CNY (¥)	Jun. 30, 2016CNY (¥)	Mar. 31, 2016USD ($)	Mar. 31, 2016CNY (¥)	Dec. 31, 2015USD ($)	Dec. 31, 2015CNY (¥)	Aug. 31, 2015CNY (¥)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loan receivable-non current				$ 44,925,000		$ 44,925,000							$ 39,834,173
Interest income, accrued				1,865,805	$ 1,383,142	4,909,014	$ 4,227,124
Loan receivable-current				5,990,000		$ 5,990,000							0
Xinjiang Deyuan [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loan receivable-non current											$ 6,190,147	¥ 41,336,539	$ 38,734,853	¥ 258,663,461
Cooperation Agreement Loan Principal Amount			$ 44,925,000												¥ 300,000,000
Debt Instrument, Interest Rate, Stated Percentage			6.00%												6.00%
Debt Instrument, Maturity Date			Jul. 31, 2018
Debt Instrument, Collateral						Deyuan Shareholder’s 58.02% equity interest in Xinjiang Deyuan
Interest income, accrued				638,622		$ 638,622
Proceeds from Interest Received				1,985,767		1,985,767
Xinjiang Deyuan [Member] | Short-term Debt [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Cooperation Agreement Loan Principal Amount		$ 5,990,000								¥ 40,000,000
Debt Instrument, Interest Rate, Stated Percentage		6.00%								6.00%
Debt Instrument, Maturity Date		Sep. 20, 2016
Interest income, accrued				79,906		79,906
Loan receivable-current								$ 5,990,000	¥ 40,000,000
Debt Instrument, Interest Rate Terms	The Company has the right to charge an interest rate of 9% per annum for any overdue loan since September 21, 2016 according to loan agreement.
Proceeds from Interest Received				$ 60,012		$ 60,012

INCOME TAX (Narrative) (Details

INCOME TAX (Narrative) (Details)	3 Months Ended		9 Months Ended		36 Months Ended	120 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2020
Effective income tax rate	17.00%	17.00%	16.00%	16.00%
Shandong Taibang [Member] | Scenario, Forecast [Member]
Preferential Income Tax Rate					15.00%
Guizhou Taibang [Member] | Scenario, Forecast [Member]
Preferential Income Tax Rate						15.00%

OPTIONS AND NONVESTED SHARES (N

OPTIONS AND NONVESTED SHARES (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Warrants and Options Disclosure [Line Items]
Stock compensation expense to be recognized with respect to non-vested shares	$ 89,756,842		$ 89,756,842
Stock compensation expense with respect to non-vested shares weighted average vesting period			2 years 11 months 23 days
General and Administrative Expense [Member]
Warrants and Options Disclosure [Line Items]
Stock compensation expense related to options	162,047	$ 243,578	$ 649,203	$ 874,413
Stock compensation expense related to nonvested shares	$ 6,846,521	$ 3,363,835	$ 15,666,464	$ 6,766,481

SCHEDULE OF STOCK OPTIONS ACTIV

SCHEDULE OF STOCK OPTIONS ACTIVITY (Details) - Stock Option [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding at beginning	651,897
Number of Options, Granted	0
Number of Options, Exercised	(304,826)
Number of Options, Forfeited and expired	0
Number of Options, Outstanding at ending	347,071	651,897
Number of Options, Vested	347,071
Number of Options, Exercisable	347,071
Weighted Average Exercise Price, Outstanding at beginning	$ 10.44
Weighted Average Exercise Price, Exercised	10.54
Weighted Average Exercise Price, Outstanding at ending	10.35	$ 10.44
Weighted Average Exercise Price, Vested	10.35
Weighted Average Exercise Price, Exercisable	$ 10.35
Weighted Average Remaining Contractual Term in Years, Outstanding	4 years 2 months 23 days	5 years 2 months 26 days
Weighted Average Remaining Contractual Term in Years, Vested	4 years 2 months 23 days
Weighted Average Remaining Contractual Term in Years, Exercisable	4 years 2 months 23 days
Aggregate Intrinsic Value, Outstanding at beginning	$ 86,064,461
Aggregate Intrinsic Value, Exercised	(31,741,472)
Aggregate Intrinsic Value, Outstanding at ending	39,612,865	$ 86,064,461
Aggregate Intrinsic Value Vested	39,612,865
Aggregate Intrinsic Value, Exercisable	$ 39,612,865

SCHEDULE OF NONVESTED SHARES AC

SCHEDULE OF NONVESTED SHARES ACTIVITY (Details) - Non Vested Shares [Member]	9 Months Ended
	Sep. 30, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of nonvested shares, Outstanding at beginning | shares	669,100
Number of nonvested shares, Granted | shares	511,200
Number of nonvested shares, Vested | shares	(252,650)
Number of nonvested shares, Forfeited | shares	(12,500)
Number of nonvested shares, Outstanding at ending | shares	915,150
Grant date weighted average fair value, Outstanding at beginning | $ / shares	$ 77.49
Grant date weighted average fair value, Granted | $ / shares	119.75
Grant date weighted average fair value, Vested | $ / shares	66.1
Grant date weighted average fair value, Forfeited | $ / shares	66.74
Grant date weighted average fair value, Outstanding at ending | $ / shares	$ 104.39

SCHEDULE OF SALES BY PRODUCT TY

SCHEDULE OF SALES BY PRODUCT TYPE (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Product Information [Line Items]
Sales	$ 86,525,885	$ 78,750,577	$ 263,534,751	$ 228,173,360
Others [Member]
Product Information [Line Items]
Sales	4,292,702	3,150,799	12,428,522	7,264,251
Human Albumin [Member]
Product Information [Line Items]
Sales	32,050,728	30,442,931	102,387,387	85,538,413
Human Immunoglobulin For Intravenous Injection [Member]
Product Information [Line Items]
Sales	28,608,129	32,610,967	93,439,551	99,552,008
Other Immunoglobulin Products [Member]
Product Information [Line Items]
Sales	13,449,552	4,951,787	30,555,619	15,936,561
Placenta Polypeptide [Member]
Product Information [Line Items]
Sales	$ 8,124,774	$ 7,594,093	$ 24,723,672	$ 19,882,127

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Narrative) (Details)	1 Months Ended														3 Months Ended			9 Months Ended				12 Months Ended
	Sep. 30, 2016USD ($)shares	Aug. 31, 2016USD ($)	Aug. 31, 2016CNY (¥)	Jul. 31, 2016USD ($)	Jul. 31, 2016CNY (¥)	Jul. 31, 2014USD ($)	Jul. 31, 2014CNY (¥)	Nov. 30, 2010USD ($)	Nov. 30, 2010CNY (¥)	Oct. 31, 2010USD ($)	Oct. 31, 2010CNY (¥)	May 31, 2009shares	Jun. 30, 2007shares	May 31, 2007USD ($)shares	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Jun. 30, 2010shares	Sep. 30, 2016USD ($)	Sep. 30, 2016CNY (¥)	Sep. 30, 2015USD ($)	Sep. 30, 2015CNY (¥)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)shares	Dec. 31, 2014CNY (¥)shares	Dec. 31, 2013shares	Sep. 30, 2016CNY (¥)	Nov. 30, 2013shares	Jan. 31, 2010	May 31, 2007CNY (¥)shares
Interest Expense | $															$ 57,661	$ 101,290		$ 234,739		$ 1,533,971
Plasma [Member]
Purchase commitment amount | $																		57,200,000
Capital Addition Purchase Commitments [Member]
Capital Commitment Amount | $																		27,800,000
Dispute with Certain Individual Investor over Certain Capital Injection into Guizhou Taibang [Member]
Controlling interest of Guizhou Taibang's shareholders														91.00%															91.00%
Issuance of an additional 20,000,000 shares of Guizhou Taibang														20,000,000
Remaining 9% noncontrolling interest														9.00%															9.00%
Investors agreed to invest														$ 7,631,260															¥ 50,960,000
21.4%, of Guizhou Taibang's equity interests														21.40%															21.40%
Subscribed for 1,800,000 shares														1,800,000															1,800,000
Share of the 20,000,000 shares being offered														20,000,000															20,000,000
Penalty																		$ 51,155	¥ 341,600
Penalty Imposed By The Agreement																		1.00%	1.00%
Interest Expense																		$ 2,829,654	¥ 18,895,852
Equity Method Investment, Ownership Percentage																												14.35%
Payable to investors	$ 5,115,460														5,115,460			5,115,460								¥ 34,160,000
Guizhou Taibang attempted to return the originally received fund										$ 5,115,460	¥ 34,160,000
Another investor accepted the returned fund								$ 1,677,200	¥ 11,200,000
Dispute with Jie'an over Certain Capital Injection into Guizhou Taibang [Member]
Investors agreed to invest														$ 7,631,260															¥ 50,960,000
Guizhou Taibang received from Jie'an														$ 970,380															¥ 6,480,000
Denied the rights of first refusal of Jie'an over the 18,200,000 shares												18,200,000
Jie'an alleged right to acquire common stock shares in a lawsuit													18,200,000
Requested that Guizhou Taibang register its 1.8 million shares of additional capital infusion with the local AIC																	1,800,000
Payables to Jie an for the additional funds received	754,740														754,740			754,740								5,040,000
Payables to Jie an for over-paid subscription	215,640														215,640			215,640								1,440,000
Payable to Jie an for the accrued interest	$ 586,082														$ 586,082			$ 586,082								¥ 3,913,734
Common Stock, Capital Shares Reserved for Future Issuance																											20,000,000
Payment to trial court to be held in escrow																					¥ 22,639,227	$ 3,390,224
Guizhou Taibang to pay accumulated dividends associated with these shares and the related interest expenses to Jiean						$ 2,067,927	¥ 13,809,197
The appellate court ordered Guizhou Taibang to pay Jiean its share of accumulated dividends associated with these shares plus the related interest expenses																							$ 2,746,299	¥ 18,339,227
The appellate court ruled in favor of Jie'an supporting its request to register 1.8 million shares																							1,800,000	1,800,000
Consideration To Noncontrolling Interest Holders For Withdraw All Of Capital Contribution				$ 62,146,250	¥ 415,000,000
Payment Of First Installment To Noncontrolling Interest Holders		$ 13,502,700	¥ 90,000,000
Requesting Guizhou Taibang to register 1.8 million shares under its name with the local AIC																									1,800,000
1.8 million shares in dispute	1,800,000

NET INCOME PER SHARE - (Schedul

NET INCOME PER SHARE - (Schedule Of Computation Of Basic And Diluted Net Income Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Net income attributable to China Biologic Products, Inc.	$ 28,391,361	$ 22,876,550	$ 85,341,651	$ 72,762,981
Earnings allocated to participating nonvested shares	(888,528)	(572,297)	(2,314,921)	(1,656,974)
Net income used in basic/diluted net income per common stock	$ 27,502,833	$ 22,304,253	$ 83,026,730	$ 71,106,007
Weighted average shares used in computing basic net income per common stock	26,957,205	25,992,776	26,748,141	25,280,538
Diluted effect of stock options	339,913	1,063,439	444,967	1,208,192
Weighted average shares used in computing diluted net income per common stock	27,297,118	27,056,215	27,193,108	26,488,730
Net income per common stock - basic	$ 1.02	$ 0.86	$ 3.1	$ 2.81
Net income per common stock - diluted	$ 1.01	$ 0.82	$ 3.05	$ 2.68